Cc. Chow et al., COMPARISON OF INSULIN WITH OR WITHOUT CONTINUATION OF ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF SECONDARY FAILURE IN NIDDM PATIENTS, Diabetes care, 18(3), 1995, pp. 307-314
Citations number
34
Categorie Soggetti
Endocrynology & Metabolism","Medicine, General & Internal
OBJECTIVES - Optimal insulin regimens for non-insulin-dependent diabet
es mellitus (NIDDM) patients with secondary failure are controversial.
We evaluated the efficacy, side effects, and quality of life of patie
nts receiving insulin either alone or in combination with their previo
us oral hypoglycemic agents (OHAs). RESEARCH DESIGN AND METHODS - Fift
y-three Chinese patients with NIDDM (mean age 53.9 +/- 12.6 years, dur
ation of diabetes 9.0 +/- 4.9 years, body wt 60.4 +/- 13.3 kg with cor
responding body mass index 24.2 +/- 4.3 kg/m(2), receiving the maximum
dose of sulfonylurea and/or metformin) were confirmed to have OHA fai
lure. Twenty-seven patients were randomized to continue OHAs and were
given additional bedtime insulin (combination group); 26 patients were
randomized to insulin therapy alone with twice-daily insulin (insulin
group). insulin doses were increased incrementally, aiming at fasting
plasma glucose (FPG) <7.8 mmol/l during a stabilization period of up
to 8 weeks. Insulin dosage, body weight, glycemic control, and quality
of life were assessed before and at 3 and 6 months after stabilizatio
n. RESULTS - Both groups showed similar improvement of glycemic contro
l. For the combination group, FPG decreased from 13.5 +/- 2.7 to 8.9 /- 3.0 mmol/l at 3 months (P < 0.0001) and to 8.6 +/- 2.5 mmol/l at 6
months (P < 0.0001). For the insulin group, FPG decreased from 13.5 +/
- 3.6 to 7.5 +/- 3.0 mmol/l at 3 months (P < 0.0001) and to 9.8 +/- 3.
5 mmol/l at 6 months (P < 0.0001). No significant differences were obs
erved between the groups. Similarly, both groups had significant impro
vement of fructosamine and glycosylated hemoglobin (HbA(1c)). Fructosa
mine fell from a mean of 458 to 365 mu mol/l at 3 months (P < 0.0001)
and to 371 mu mol/l at 6 months (P < 0.0001) and from 484 to 325 mu mo
l/l at 3 months (P < 0.0001) and to 350 mu mol/l at 6 months (P < 0.00
01) for the combination and insulin groups, respectively. HbA(1c) decr
eased from 10.2 to 8.4% at 3 months (P < 0.0001) and to 8.7% at 6 mont
hs (P < 0.0001) in the combination group and from 10.7 to 7.8% at 3 mo
nths (P < 0.0001) and to 8.4% at 6 months (P < 0.0001) in the insulin
group. Despite similar improvement of glycemia, insulin requirements w
ere very different. At 3 months, the combination group was receiving a
mean of 14.4 U/day compared with 57.5 U/day in the insulin group (P <
0.0001). Similar findings were observed at 6 months (15.0 vs. 57.2 U/
day, P < 0.0001). Both groups gained weight. However, for the combinat
ion group, weight gain was 1.6 +/- 1.8 kg at 3 months and 2.1 +/- 2.5
kg at 6 months (both P < 0.0001 vs. baseline), whereas for the insulin
group, weight gain was 3.5 +/- 4.3 and 5.2 +/- 4.1 kg, respectively (
both P < 0.0001 vs, baseline). Weight gain was significantly greater i
n the insulin group (P < 0.05 at 3 months, and P < 0.005 at 6 months).
Fasting plasma triglyceride decreased in the insulin group (1.8 +/- 1
.0 to 1.4 +/- 0.8 mmol/l at 3 months [P < 0.005] and to 1.4 +/- 0.7 mm
ol/l at 6 months [P < 0.02]) but not in the combination group, No chan
ges were observed in total and high-density lipoprotein cholesterol. N
o severe hypoglycemic reactions were recorded in either group. Mild re
actions occurred with similar frequency in both groups. Well-being and
quality of life improved significantly in both groups. The majority o
f patients (82.7%) wanted to continue insulin beyond 6 months, irrespe
ctive of the treatment group. CONCLUSIONS - In NIDDM patients with sec
ondary OHA failure, therapy with a combination of OHAs and insulin and
with insulin alone was equally effective and well tolerated. However,
combination therapy was associated with a lower insulin dose and less
weight gain. Combination treatment may be considered when OHA failure
occurs as a potential intermediate stage before full insulin